Methazolamide is a carbonic anhydrase inhibitor that exhibits anti-glaucoma and anti-diabetic activities. Methazolamide decreases blood glucose and Hb1(Ac) levels and improves glucose tolerance. This compound is clinically used to treat glaucoma, as it lowers intraocular pressure. In some models, methazolamide may exhibit antiepileptic/anticonvulsant activity.
| Cas No. | 554-57-4 |
|---|---|
| Purity | ≥98% |
| Formula | C5H8N4O3S2 |
| Formula Wt. | 236.27 |
| IUPAC Name | N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M1579 Info Sheet PDF |
|---|
Syrjänen L, Parkkila S, Scozzafava A, et al. Sulfonamide inhibition studies of the β carbonic anhydrase from Drosophila melanogaster. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2797-801. PMID: 24852120.
Konstantopoulos N, Molero JC, McGee SL, et al. Methazolamide is a new hepatic insulin sensitizer that lowers blood glucose in vivo. Diabetes. 2012 Aug;61(8):2146-54. PMID: 22586591.
Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985 Jul;103(7):963-6. PMID: 3860197.
Torchiana ML, Lotti VJ, Stone CA. The anticonvulsant effect of carbonic anhydrase inhibitors in mice--a noradrenergic mechanism of action. Eur J Pharmacol. 1973 Mar;21(3):343-9. PMID: 4145319.
